Wendy Mcdermott
Personalreferent bei LEXICON PHARMACEUTICALS, INC.
Vermögen: 81 149 $ am 30.04.2024
Aktive Positionen von Wendy Mcdermott
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Personalreferent | 01.01.2022 | - |
Karriereverlauf von Wendy Mcdermott
Ehemalige bekannte Positionen von Wendy Mcdermott
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Sanofi Corp. | Personalreferent | 01.01.2017 | 01.01.2019 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Personalreferent | 01.01.2019 | - |
Ausbildung von Wendy Mcdermott
| State University of New York College at Plattsburgh | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Börse
- Insiders
- Wendy Mcdermott
- Erfahrung